The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study

被引：7
作者：
Zinzani, Pier Luigi [1 ]
Rigacci, Luigi [2 ]
Cox, Maria Cristina [3 ]
Devizzi, Liliana [4 ]
Fabbri, Alberto [5 ]
Zaja, Francesco [6 ]
Di Rocco, Alice [7 ]
Rossi, Giuseppe [8 ]
Storti, Sergio [9 ]
Fattori, Pier Paolo [10 ]
Argnani, Lisa [1 ]
Vitolo, Umberto [11 ]
机构：
[1] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy
[2] Careggi Hosp, Dept Haematol, Florence, Italy
[3] Univ Roma La Sapienza, Dept Clin & Expt Med, AO St Andrea, Haematol Unit, Rome, Italy
[4] Natl Canc Inst, Div Hematol, Milan, Italy
[5] S Maria alle Scotte Hosp, Div Haematol, Siena, Italy
[6] AOUD SM Misericordia, DISM, Dept Haematol, Udine, Italy
[7] Sapienza Univ, Dept Cellular Biotechnol & Haematol, Rome, Italy
[8] Spedali Civil Brescia, Dept Haematol, Brescia, Italy
[9] Univ Cattolica Sacro Cuore, Ctr High Technol Res & Educ Biomed Sci, Campobasso, Italy
[10] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[11] AO Citta Salute & Sci Torino, Turin, Italy
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷 / 01期
关键词：
MANTLE CELL LYMPHOMAS; B-CELL; RITUXIMAB; INDOLENT; TRIAL; DEXAMETHASONE; MONOTHERAPY; RESPONSES;
D O I：
10.1080/10428194.2016.1184755
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：226 / 229
页数：4
相关论文
共 15 条
  • [1] Combined Lenalidomide, Low-Dose Dexamethasone, and Rituximab Achieves Durable Responses in Rituximab-Resistant Indolent and Mantle Cell Lymphomas
    Ahmadi, Tahamtan
    Chong, Elise A.
    Gordon, Amanda
    Aqui, Nicole A.
    Nasta, Sunita D.
    Svoboda, Jakub
    Mato, Anthony R.
    Schuster, Stephen J.
    [J]. CANCER, 2014, 120 (02) : 222 - 228
  • [2] Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas
    Chong, Elise A.
    Ahmadi, Tahamtan
    Aqui, Nicole A.
    Svoboda, Jakub
    Nasta, Sunita D.
    Mato, Anthony R.
    Walsh, Kristy M.
    Schuster, Stephen J.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (08) : 1835 - 1842
  • [3] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
    Coiffier, Bertrand
    Thieblemont, Catherine
    Van Den Neste, Eric
    Lepeu, Gerard
    Plantier, Isabelle
    Castaigne, Sylvie
    Lefort, Sophie
    Marit, Gerald
    Macro, Margaret
    Sebban, Catherine
    Belhadj, Karim
    Bordessoule, Dominique
    Ferme, Christophe
    Tilly, Herve
    [J]. BLOOD, 2010, 116 (12) : 2040 - 2045
  • [4] Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment
    Davis, TA
    Grillo-López, AJ
    White, CA
    McLaughlin, P
    Czuczman, MS
    Link, BK
    Maloney, DG
    Weaver, RL
    Rosenberg, J
    Levy, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3135 - 3143
  • [5] Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
    Gribben, John G.
    Fowler, Nathan
    Morschhauser, Franck
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) : 2803 - U127
  • [6] Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like Than in Germinal Center B-Cell-Like Phenotype
    Hernandez-Ilizaliturri, Francisco J.
    Deeb, George
    Zinzani, Pier L.
    Pileri, Stefano A.
    Malik, Farhana
    Macon, William R.
    Goy, Andre
    Witzig, Thomas E.
    Czuczman, Myron S.
    [J]. CANCER, 2011, 117 (22) : 5058 - 5066
  • [7] Non-Hodgkin lymphoma
    Shankland, Kate R.
    Armitage, James O.
    Hancock, Barry W.
    [J]. LANCET, 2012, 380 (9844) : 848 - 857
  • [8] Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma
    Tuscano, Joseph M.
    Dutia, Mrinal
    Chee, Karen
    Brunson, Ann
    Reed-Pease, Christine
    Abedi, Mehrdad
    Welborn, Jeanna
    O'Donnell, Robert T.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (03) : 375 - 381
  • [9] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
    Wang, M.
    Fowler, N.
    Wagner-Bartak, N.
    Feng, L.
    Romaguera, J.
    Neelapu, S. S.
    Hagemeister, F.
    Fanale, M.
    Oki, Y.
    Pro, B.
    Shah, J.
    Thomas, S.
    Younes, A.
    Hosing, C.
    Zhang, L.
    Newberry, K. J.
    Desai, M.
    Cheng, N.
    Badillo, M.
    Bejarano, M.
    Chen, Y.
    Young, K. H.
    Champlin, R.
    Kwak, L.
    Fayad, L.
    [J]. LEUKEMIA, 2013, 27 (09) : 1902 - 1909
  • [10] Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
    Wiernik, Peter H.
    Lossos, Izidore S.
    Tuscano, Joseph M.
    Justice, Glen
    Vose, Julie M.
    Cole, Craig E.
    Lam, Wendy
    McBride, Kyle
    Wride, Kenton
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Habermann, Thomas M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (30) : 4952 - 4957
12